Micrometastatic bone marrow cells at diagnosis have no impact on survival of primary breast cancer patients with extensive axillary lymph node involvement treated with stem cell-supported high-dose chemotherapy |
| |
| Authors: | Schneeweiss, A. Diel, I. Hensel, M. Kaul, S. Sinn, H.-P. Unnebrink, K. Rudlowski, C. Lauschner, I. Schuetz, F. Egerer, G. Haas, R. Ho, A. D. Bastert, G. |
| |
| Affiliation: | 1 University of Heidelberg, Department of Gynecology and Obstetrics, Heidelberg; 2 Institute for Gynecological Oncology, Mannheim; 3 University of Heidelberg, Department of Internal Medicine V, Heidelberg; 4 University of Heidelberg, Department of Pathology, Heidelberg; 5 University of Heidelberg, Coordination Center for Clinical Trials, Heidelberg; 6 University of Düsseldorf, Department of Hematology and Oncology, Düsseldorf, Germany |
| |
| Abstract: | 
Backround: To determine the impact of micrometastatic bone marrowcells (MMC) on survival in high-risk primary breast cancer (HRPBC)patients treated with high-dose chemotherapy (HDCT) and autologousstem cell transplantation (ASCT). Patients and methods: Ninety-one HRPBC patients (73 patientswith |
| |
| Keywords: | high-dose chemotherapy micrometastatic bone marrow cells primary breast cancer prognostic impact survival |
| 本文献已被 ScienceDirect Oxford 等数据库收录！ |
|
